Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Faculty Opinions recommendation of Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727591680.793534051 ◽

2017 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Faculty Opinions recommendation of Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727591680.793555533 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

P67: LONG-TERM MANAGEMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1-YEAR RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL (CHRONOS)

Internal Medicine Journal ◽

10.1111/imj.67_13578 ◽

2017 ◽

Vol 47 ◽

pp. 25-25 ◽

Cited By ~ 5

Author(s):

A Blauvelt ◽

M Gooderham ◽

P Foley ◽

Griffiths CEM ◽

JC Cather ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal

British Journal of Dermatology ◽

10.1111/bjd.16520 ◽

2018 ◽

Vol 178 (4) ◽

Author(s):

J. Thomson ◽

A.G.H. Wernham ◽

H.C. Williams

Keyword(s):

Atopic Dermatitis ◽

Critical Appraisal ◽

Topical Corticosteroids ◽

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.054 ◽

2020 ◽

Vol 83 (5) ◽

pp. 1282-1293 ◽

Cited By ~ 10

Author(s):

Amy S. Paller ◽

Elaine C. Siegfried ◽

Diamant Thaçi ◽

Andreas Wollenberg ◽

Michael J. Cork ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded

Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids ( LIBERTY AD CHRONOS ): a critical appraisal

British Journal of Dermatology ◽

10.1111/bjd.16317 ◽

2018 ◽

Vol 178 (4) ◽

pp. 897-902 ◽

Cited By ~ 8

Author(s):

J. Thomson ◽

A.G.H. Wernham ◽

H.C. Williams

Keyword(s):

Atopic Dermatitis ◽

Critical Appraisal ◽

Topical Corticosteroids ◽

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.99 ◽

2020 ◽

Vol 4 (6) ◽

pp. s99

Author(s):

Jonathan Silverberg ◽

Andrew Pink ◽

Christina Olsen ◽

Stephan Weidinger

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Topical Corticosteroids

Abstract not available.

27697 Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.650 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB159

Author(s):

Andrew Blauvelt ◽

Jean-Philippe Lacour ◽

Darryl Toth ◽

Vivian Laquer ◽

Stefan Beissert ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Term Efficacy ◽

Extension Trial

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor